AWCI
CRL icon

Alpine Woods Capital Investors’s Charles River Laboratories CRL Stock Holding History

Alpine Woods Capital Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,145
Closed -$262K – 177
2024
Q1 		$262K Hold
1,145
– – 0.05% 162
2023
Q4 		$271K Sell
1,145
-110
-9% -$21.6K 0.04% 157
2023
Q3 		$246K Sell
1,255
-135
-10% -$27.7K 0.04% 152
2023
Q2 		$292K Hold
1,390
– – 0.05% 142
2023
Q1 		$281K Sell
1,390
-100
-7% -$22.7K 0.04% 155
2022
Q4 		$325K Hold
1,490
– – 0.05% 155
2022
Q3 		$293K Hold
1,490
– – 0.04% 174
2022
Q2 		$319K Hold
1,490
– – 0.04% 176
2022
Q1 		$423K Sell
1,490
-50
-3% -$15.4K 0.04% 170
2021
Q4 		$580K Sell
1,540
-155
-9% -$60.2K 0.06% 167
2021
Q3 		$699K Hold
1,695
– – 0.07% 163
2021
Q2 		$627K Sell
1,695
-80
-5% -$26.7K 0.07% 173
2021
Q1 		$514K Sell
1,775
-5,200
-75% -$1.45M 0.06% 183
2020
Q4 		$1.74M Sell
6,975
-1,300
-16% -$310K 0.21% 124
2020
Q3 		$1.87M Sell
8,275
-2,050
-20% -$425K 0.28% 110
2020
Q2 		$1.8M Sell
10,325
-1,075
-9% -$172K 0.35% 88
2020
Q1 		$1.44M Sell
11,400
-100
-0.9% -$15K 0.32% 87
2019
Q4 		$1.76M Hold
11,500
– – 0.33% 72
2019
Q3 		$1.52M Hold
11,500
– – 0.28% 74
2019
Q2 		$1.63M Hold
11,500
– – 0.34% 73
2019
Q1 		$1.67M Buy
11,500
+5,100
+80% +$670K 0.36% 68
2018
Q4 		$724K Hold
6,400
– – 0.17% 130
2018
Q3 		$861K Sell
6,400
-100
-2% -$12.3K 0.18% 115
2018
Q2 		$730K Hold
6,500
– – 0.16% 120
2018
Q1 		$694K Hold
6,500
– – 0.04% 276
2017
Q4 		$711K Hold
6,500
– – 0.04% 274
2017
Q3 		$702K Sell
6,500
-9
-0.1% -$925 0.04% 280
2017
Q2 		$658K Buy
6,509
+9
+0.1% +$828 0.04% 276
2017
Q1 		$585K Buy
+6,500
New +$552K 0.03% 294
2015
Q4 		– Sell
-5,000
Closed -$318K – 462
2015
Q3 		$318K Buy
+5,000
New +$359K 0.02% 393

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Alpine Woods Capital Investors's CRL Position: Q2 2024 in Review

Alpine Woods Capital Investors sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 1,145 shares — an estimated $262K sold.

Alpine Woods Capital Investors first reported a position in CRL in Q3 2015 and held it in 30 quarters. The position peaked at $1.87M in Q3 2020. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Alpine Woods Capital Investors reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 1,145 Charles River Laboratories shares in Q2 2024, an estimated $262K.
  • Alpine Woods Capital Investors first reported a position in Charles River Laboratories in Q3 2015 and held it in 30 quarters.
  • Alpine Woods Capital Investors's Charles River Laboratories position peaked at $1.87M in Q3 2020.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2024, filed 6 Aug 2024.